Breath biopsy specialist, Owlstone Medical, has entered into a research agreement with biotech company, Bicycle Therapeutics plc, to access its bicyclic peptide technology.
Challenging target profiles can be targeted more efficiently than traditional drug discovery using Exscientia’s AI-driven precision design platform, its CEO says.
In the second and final part of an interview with Medable’s chief growth officer and women’s health champion, Sanskriti Thakur, discover her views on vital changes that need to be made. She discusses ways to ensure the importance of women’s roles in clinical...
Non-clinical research has been published about roginolisob, iOnctura’s non-ATP competitive alloseteric modulator of PI3Kδ, for the potential treatment of patients with solid and hematological tumors.
Earlier this year, Akorn Pharmaceuticals fell into bankruptcy, and now an alliance of stakeholders have released a report outlining potential supply disruption to a number of medications.
The funding will be split between 17 US non-profit organizations this year, as the company reveals the broader progress it has made towards its long-term inclusion and diversity goals.
Despite diversity being spoken about more than ever before, research discovers clinical trials are less representative of the US population compared to a decade prior.
Positive data from a phase 2 clinical trial has proven the general mechanism of action of SK channel inhibition for treatment of atrial fibrillation (AF), an abnormal heart rhythm.
After completing the acquisition of Aveo, the Korean chemical company wants its subsidiary to become a global leader in the therapeutic area within five years.
Poolbeg Pharma plc has been granted a patent by the US Patent and Trademark Office (USPTO) for ways of treating hypercytokinaemia using a small molecule immunomodulator.
Small molecule drug, Niraparib combined with abiraterone acetate (AA) and prednisone (P) significantly reduces the risk of disease progression, or death, in patients with a type of prostate cancer, a consultant in Spain has said.
Charité – Universitätsmedizin Berlin, one of Europe’s largest university hospitals is collaborating with UK-based Exscientia to make use of an artificial intelligence-driven precision medicine platform in haematological cancers.
When the pandemic broke, the whole world was thrown onto a steep learning curve. Everyone had to find new ways to adapt in their day to day lives as well as their working lives. There was no exception with clinical trials, with patients unable to attend...
Patient recruitment and retention is an ongoing issue for everyone working in the clinical trials field. Over recent weeks, OSP has interviewed or spoken to a number of companies about their solutions.
The two partners will pool capabilities to provide an expanded service to their clients, which will see Koneksa provide its digital biomarkers tools and SSI Strategy its expertise in drug development.
UC San Francisco will conduct a six-month clinical trial on hypertrophic cardiomyopathy, which will rely on feedback from Vivalink’s biometric data platform.
Our world is getting greener – or at least trying to with more people turning to electric vehicles, buying local seasonal fruit and vegetables, cafes and restaurants adopting paper straws and a growth in sales of eco-friendly home products, to name a...
In the first of a two-part interview with Medable’s chief growth officer, Sanskriti Thakur, we will learn about why she thinks the world of medicine is letting women down, what the future holds and how everyone should be paying more attention.
Mutation in the progranulin (GRN) gene is just one of several hereditary factors that can cause frontotemporal dementia, a rare and rapidly progressive neurodegenerative disease.
Year on year, the SCOPE summit brings thousands of people working in the pharma field together and the last one attracted more than 2,300 leaders in clinical operations and research.
The Japanese clinical trial company and the technology provider agree a collaboration deal, as Japan encourages the digitalization of clinical trials and the use of DCT approaches.
The two companies announce a business combination via a proposed all share merger transaction, effectively combining the pipelines and workforce of the two biotechs.
The organization collaborates with companies across the pharma industry to create new, free resources to help improve diversity, equity, and inclusion in digitized clinical trials.
Recruiting and retaining patients on trials is one of the biggest hurdles the pharma industry faces, we spoke to Jonathan Eilberg to find out why and ways to tackle the ongoing issues.
Father and software engineer, Vincent Keunen combined his personal experience of leukemia and his son's bone cancer with his professional skills to provide all patients with a tool to manage their health information on their smartphone.
Guest article - Patient ID/recruitment and retention
The company published a report finding that almost a fifth of trial sites only recruit one patient, Phesi’s CEO explained to Outsourcing-Pharma what the reaction at the event had been.
The two companies will come together to provide a ‘patient-centered solution’ for clinical research, combing uMotif’s patient engagement platform with ActiGraph’s wearable technology.
One of the biggest questions being posed at this year's SCOPE summit, is whether the term 'decentralized clinical trials' will become redundant, as it forms the norm.
Caroline Jackson is executive vice president for patient services at mdgroup and she will be delivering a presentation at SCOPE called 'Achieving the Impossible: Maximizing Patient Experience and Data Quality in a Complex Rare Disease Program.'...
The US Food and Drug Administration (FDA) has approved AstraZeneca’s asthma treatment, Airsupra after positive results from a global phase 3 clinical trial.
The not-for-profit organization published its fair inclusion score to measure and rank pharmaceutical companies on their inclusion of women, older adults, and racial and ethnic minoritized patients.
The cryptocurrency space suffered through a torrid, scandal-marked 2022 but there remains interest in using the blockchain infrastructure that underpins the sector in other contexts. In a recent review of the potential of the blockchain in healthcare,...
On Friday (Jan 6), the US Food and Drink Administration (FDA) granted a licence for another anti-amyloid drug – lecanemab – to treat Alzheimer’s disease.
After a successful evaluation of its whole-genome sequencing-based test for solid tumor minimal residual disease (MRD) C2i Genomics announced today (January 5) that they have extended their collaboration with AstraZeneca.
